The Advances in Gastrointestinal Cancer Resource Centre Introduction
The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting-edge data to practising healthcare professionals. Our aim is to provide clinically relevant information, in order to enhance your ability to provide optimal care for your patients with gastrointestinal (GI) cancer. We offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, functions as an information hub for healthcare professionals
Advances in Gastrointestinal Cancer having focused initially on gastric cancer, has now expanded its scope to include all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in the management of GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
Breaking news from ESMO 2016 Congress, Copenhagen, Denmark
ESMO 2016 Congress highlights
- When is the optimal time for surgery following CRT for locally advanced rectal cancer? Results of the UK 6 vs...
- Gastroesophageal cancer surgery in high volume centres is associated with less postoperative mortality regardless of co-morbidity status Centralisation of surgery...
Article of the month
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Lancet Oncol. 2016 Dec;17(12):1697-1708.
Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Dannenberg AJ, et al.J Clin Oncol. 2016 Sep 6. [Epub ahead of print]
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, et al.Lancet Oncol 2016;17:1426-1434.
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, et al.Lancet Oncol 2016;17:1543-1557.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al.Lancet 2016 Dec. [Epub ahead of print]
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, et al.Ann Oncol 2016;27:2196-2203.
Director of the Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre and Director of Clinical Research
- Feb 201724Feb 201727
Zing ConferencesOmni La Costa Resort & SpaCarlsbad, United States
- Feb 201724Feb 201726
Cleveland ClinicDisney’s Grand Floridian ResortLake Buena Vista, United States